Sign up to save your podcasts
Or
Share Timely basal insulin in T2D: A look at treatment intensification approaches in practice
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Timely basal insulin in T2D: A look at treatment intensification approaches in practice
Why does the timely addition of basal insulin remain an important issue in practice, despite the increasing use of glucagon-like peptide-1 receptor agonists (GLP1-RA) seen in recent years?
Our host, Dr. Ronald Goldenberg, takes a deeper look into this topic with Dr. Meera Luthra, an endocrinologist at St. Joseph’s Healthcare Hamilton and Clinician Educator at McMaster University.
The episode discusses clinical inertia and approaches you may use in practice for treatment intensification to improve glycemic control, particularly around initiating basal insulin, for patients with type 2 diabetes (T2D). The importance of real-world studies is discussed, namely, the RESTORE-G and DELIVER-G studies, in the context of the efficacy behind adding basal insulin to GLP1-RA therapy to optimize glycemic control.
The RESTORE-G study examined treatment intensification approaches to adding basal insulin for patients with T2D already on a GLP1-RA therapy. The DELIVER-G study looked at the impact of the addition of second-generation basal insulin, glargine U300 for patients with T2D on GLP1-RA therapy. Our experts also dive into the relevance and applicability of some practical approaches for treatment intensification to improve glycemic control in clinical practice.
Don’t miss the conversation!
The views and opinions expressed in this episode are those of the speakers, and do not necessarily reflect the views or positions of any entities they represent.
Declaration of conflict of interest:
Dr. Ronald Goldenberg:
- Direct financial relationship, including receipt of honoraria: Abbott, Amgen, Bayer, Boehringer Ingelheim, CCRN, CMSKTRG, Eli Lilly, EOCI, Hamilton Academy of Medicine, HIT Global, HLS, Insulet, Janssen, LiV, LMC Physician Inc., MD Briefcase, Novartis, Novo Nordisk, Sanofi, SL Solutions, Unik, Virtual Hallway Consults Inc. Membership on advisory boards or speakers’ bureaus: Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, HLS, Janssen, Novo Nordisk, Sanofi. Funded grants, research, or clinical trials: Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, Novo Nordisk, Sanofi.
Dr. Meera Luthra:
- Direct financial relationship, including receipt of honoraria: Amgen, Bayer, Boehringer Ingelheim, Dexcom, Eisai, Pfizer, Eli Lilly, Novo Nordisk, Sanofi. Membership on advisory boards or speakers’ bureaus: Dexcom, HLS Therapeutics, Novo Nordisk, Sanofi. Funded grants, research, or clinical trials: None
MAT-CA-2400799
View all episodes
By Diving Into DiabetesWhy does the timely addition of basal insulin remain an important issue in practice, despite the increasing use of glucagon-like peptide-1 receptor agonists (GLP1-RA) seen in recent years?
Our host, Dr. Ronald Goldenberg, takes a deeper look into this topic with Dr. Meera Luthra, an endocrinologist at St. Joseph’s Healthcare Hamilton and Clinician Educator at McMaster University.
The episode discusses clinical inertia and approaches you may use in practice for treatment intensification to improve glycemic control, particularly around initiating basal insulin, for patients with type 2 diabetes (T2D). The importance of real-world studies is discussed, namely, the RESTORE-G and DELIVER-G studies, in the context of the efficacy behind adding basal insulin to GLP1-RA therapy to optimize glycemic control.
The RESTORE-G study examined treatment intensification approaches to adding basal insulin for patients with T2D already on a GLP1-RA therapy. The DELIVER-G study looked at the impact of the addition of second-generation basal insulin, glargine U300 for patients with T2D on GLP1-RA therapy. Our experts also dive into the relevance and applicability of some practical approaches for treatment intensification to improve glycemic control in clinical practice.
Don’t miss the conversation!
The views and opinions expressed in this episode are those of the speakers, and do not necessarily reflect the views or positions of any entities they represent.
Declaration of conflict of interest:
Dr. Ronald Goldenberg:
- Direct financial relationship, including receipt of honoraria: Abbott, Amgen, Bayer, Boehringer Ingelheim, CCRN, CMSKTRG, Eli Lilly, EOCI, Hamilton Academy of Medicine, HIT Global, HLS, Insulet, Janssen, LiV, LMC Physician Inc., MD Briefcase, Novartis, Novo Nordisk, Sanofi, SL Solutions, Unik, Virtual Hallway Consults Inc. Membership on advisory boards or speakers’ bureaus: Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, HLS, Janssen, Novo Nordisk, Sanofi. Funded grants, research, or clinical trials: Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, Novo Nordisk, Sanofi.
Dr. Meera Luthra:
- Direct financial relationship, including receipt of honoraria: Amgen, Bayer, Boehringer Ingelheim, Dexcom, Eisai, Pfizer, Eli Lilly, Novo Nordisk, Sanofi. Membership on advisory boards or speakers’ bureaus: Dexcom, HLS Therapeutics, Novo Nordisk, Sanofi. Funded grants, research, or clinical trials: None
MAT-CA-2400799